Trials / Completed
CompletedNCT05728944
Phase 3 Efficacy Study of LNZ100 & LNZ101 for the Treatment of Presbyopia
A Multi-Center, Double-Masked Phase 3 Evaluation of the Safety and Efficacy of LNZ101 for the Treatment of Presbyopia
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 229 (actual)
- Sponsor
- LENZ Therapeutics, Inc · Academic / Other
- Sex
- All
- Age
- 45 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
Phase 3 Efficacy Study to evaluate the Safety and Efficacy of LNZ100 \& LNZ101 for the Treatment of Presbyopia
Detailed description
Phase 3 study to evaluate the safety and effectiveness of LNZ101 compared with LNZ100 and Vehicle for the treatment of Presbyopia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Aceclidine+Brimonidine combination ophthalmic solution | Aceclidine + Brimonidine combination ophthalmic solution |
| DRUG | Aceclidine ophthalmic solution | Aceclidine ophthalmic solution |
| DRUG | Vehicle | Proprietary vehicle ophthalmic solution |
Timeline
- Start date
- 2023-03-06
- Primary completion
- 2023-12-14
- Completion
- 2024-01-24
- First posted
- 2023-02-15
- Last updated
- 2026-02-25
- Results posted
- 2026-02-25
Locations
17 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05728944. Inclusion in this directory is not an endorsement.